AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00574574 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: anthocyanin
Description: 500mg/d of anthocyanin each day for 12 weeks (84days). Route of administration: oral capsules, 4 X 250mg capsules (125mg anthocyanin/ capsule). Dosage advice; 2 capsules to be taken with food, twice per day (n=4 in total).
Study NCT00574574 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: anthocyanin
Description: 500mg/d of anthocyanin each day for 12 weeks (84days). Route of administration: oral capsules, 4 X 250mg capsules (125mg anthocyanin/ capsule). Dosage advice; 2 capsules to be taken with food, twice per day (n=4 in total).
Study NCT02059083 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart rate variability biofeedback
Study NCT02059083 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT
Study NCT05164445 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Transbronchial forceps biopsy
Description: All patients with peripheral lung lesion suspected of lung cancer detected on the chest computed tomography (CT) and mini probe endobronchial ultrasound (RP-EBUS) scans were enrolled. Transbronchial forceps biopsy (TBFB) was performed for all these patients.
Study NCT05164445 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Transbronchial forceps biopsy+Transbronchial cryobiopsy
Description: All patients with peripheral lung lesion suspected of lung cancer detected on the chest computed tomography (CT) and RP-EBUS scans were enrolled. TBFB was performed for all these patients. In addition, all of these patients, with no contraindications, underwent transbronchial cryobiopsy (TBCB)
Study NCT01227902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retigabine IR
Description: Flexible dose between 300 mg/day (minimum) and 1200 mg/day (maximum).
Study NCT04264624 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Perioflow and Erythritol powder and ultrasonic debridement
Description: Airflow and Perioflow combined with Erythritol powder will be used as an adjunct therapy
Study NCT04264624 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airflow and Erythritol powder and ultrasonic debridement
Description: Airflow combined with Erythritol powder will be used as an adjunct therapy
Study NCT04264624 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Airflow and Erythritol powder and ultrasonic debridement
Description: Airflow combined with Erythritol powder will be used as an adjunct therapy
Study NCT04655651 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention for both groups.
Study NCT04704947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nonselective beta blocker
Description: nonselective beta blocker
Study NCT04704947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cardio-selective beta blocker group
Description: cardio-selective beta blocker group
Study NCT04704947 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: alendronate sodium
Description: alendronate sodium
Study NCT04704947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alendronate sodium
Description: alendronate sodium
Study NCT00244140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iopromide 370 mg I/mL
Description: Iopromide (Ultravist 370 mg I/mL) administered intravenously
Study NCT00244140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iopromide 300 mg I/mL
Description: Iopromide (Ultravist 300 mg I/mL) administered intravenously
Study NCT02884505 — intervention group
Intervention type: DEVICE
Intervention: Pupillometry
Description: Measures pupillary dynamics in darkness and light conditions
Study NCT02884505 — intervention group
Intervention type: BEHAVIORAL
Intervention: Psychomotor Vigilance Task
Description: Response time task measuring neurobehavioral alertness
Study NCT02884505 — intervention group
Intervention type: OTHER
Intervention: Auditory Evoked Potential
Description: Measure of electroencephalographic response to standardized auditory tones
Study NCT02884505 — intervention group
Intervention type: BEHAVIORAL
Intervention: Hypersomnia Severity Index
Description: Self-report measure of hypersomnolence
Study NCT01688531 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CD0271 0.1%/CD1579 2.5% gel
Description: one application (pea-sized amount according to the labelling) on a half-face, 5 to 7 days for 6 months
Study NCT01688531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD0271 0.1%/CD1579 2.5% gel vehicle
Description: one application (pea-sized amount according to the labelling) on a half-face, 5 to 7 days for 6 months
Study NCT03208582 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Risedronate Sodium
Description: Participants will be initially tested on the response to mechanical stimulation as a baseline and then tested again after 6 weeks treatment with Risedronate
Study NCT03208582 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Calcichew tablets
Description: Participants will take calcichew tablets during the 6 week period of risedronate treatment
Study NCT03554486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fiasp
Description: Fiasp insulin will be used for 2 weeks with the 670G hybrid closed-loop system
Study NCT03554486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Novolog
Description: Novolog insulin will be used for 2 weeks with the 670G hybrid closed-loop system
Study NCT02215811 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cells
Study NCT03555019 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Formulaid
Description: Supplementation with ARA and DHA
Study NCT03555019 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MCT-oil
Description: Supplementation with medium chain fatty acids
Study NCT02084290 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shared Decision Making Program
Description: This study is cluster randomized by study-site, Subjects enrolled at intervention sites will access an educational program and risk prediction tool. Their decisions about treatments will be compared to subjects that did not view the educational program or risk prediction tool.
Study NCT02571335 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Training
Description: Week 1: Ratio of continuous and interval training of 2:1. Entry point at day one with 20 min of continuous, physiologically defined heart rate controlled cycling at 50-60 rounds per minutes at 75% of HRpeak.~Resistance training is performed with 70% of the subjective-felt 1-round maximum with three sets and 10-12 repetitions and three exercises for the upper and lower extremities.~Week 2 Progression of endurance training: 4x5 minutes with 2 Minutes between each interval performed at 80% of HRmax Progression resistance training: 75% of the subjective-felt 1-round maximum with three sets and 8-10 repetitions and three exercises for the upper and lower extremities.~Week 3 Same as week 2.
Study NCT02571335 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Normal Training
Description: The control intervention is the normal rehabilitation program of the Valens clinic.
Study NCT04176848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CFI-400945
Description: CFI-400945 32 mg: Cycle 1: Days 1-7, then Days 15-21; Cycle 2 on: orally once daily
Study NCT04176848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Cycle 2 on: Durvalumab 1500mg IV on Day 1 (28 day cycles)
Study NCT01280877 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tACS
Description: Transorbital alternating current stimulation (tACS) is applied with a multi-channel device with paraorbital montage of 4 stimulation electrodes generating weak current pulses in predetermined firing bursts of 8 to 14 pulses. The amplitude of each current pulse was below 1000 microA. Current intensity was individually adjusted according to how well patients perceived phosphenes, i.e. any sensation of flickering light in response to the rtACS stimulation.
Study NCT01280877 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: tACS is applied with the same device with equal electrodes set-up procedures but only one of four channels actually delivers current. The current intensity of this channel is individually adjusted (preselected on the side of lesioned eye) according with patient able to clearly perceive single phosphenes or any skin irritation phenomena (like weak sense of needles or vibration) whenever a single pulse is applied. The amplitude of pulses is always below 1000 microA. Current pulses are given as 1 pulse per minute during 25-35 min of session time. Session duration is equal for verum and sham patients. The perception of the single pulses leaves sham patients at the impression that they might receive the verum intervention, but total number of pulses is less than 0,5% of verum tACS.
Study NCT01739062 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic risk assessment
Study NCT00441116 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dutasteride 0.5mg oral tablets
Description: Dutasteride
Study NCT03803319 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fibre 1 (combined fibres)
Description: Dietary fibre supplement
Study NCT03803319 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fibre 2 (natural fibres)
Description: Dietary fibre supplement
Study NCT03803319 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary Supplement: placebo
Description: Dietary supplement
Study NCT02751385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microgynon
Study NCT02751385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Study NCT00862641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson
Description: IV
Study NCT00862641 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV
Study NCT04128813 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vertical whole body vibration
Description: A neuromuscular treatment using two types of whole body vibration platforms, a rotational and a vertical platform.
Study NCT03945617 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Treatment Protocol
Description: The Unified Treatment Protocol (UP) is a transdiagnostic psychotherapeutic treatment manual for emotional disorders, that is based on CBT principles and focuses on changing dysfunctional emotion regulation.
Study NCT03179605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFD06
Description: Apply twice per day for 15 days
Study NCT00888043 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: CNTO 95 and avastin
Description: STAGE 1 (Dose escalation) Cohort # subjects CNTO 95 Bevacizumab~* 2 3-6 2.5 mg/kg IV Q3 weeks 7.5 mg/kg IV Q3 weeks~* 1 3-6 2.5 mg/kg IV Q3 weeks 15 mg/kg IV Q3 weeks~  1. 3-6 5 mg/kg IV Q3weeks 15 mg/kg IV Q3 weeks~ 2. 3-6 10 mg/kg IV Q3 weeks 15 mg/kg IV Q3 weeks STAGE 2 (Biomarker) Cohort # subjects CNTO 95 Bevacizumab~ 3. 20 Recommended Phase II Dose Recommended Phase II Dose
Study NCT01419197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Description: The dose was calculated based on the patient's Baseline weight on Day 1 of each 3-week treatment cycle. The same dose was administered in subsequent cycles if the patient's weight stayed within 10% of the Baseline weight. If there was a weight change > 10%, the dose was adjusted accordingly and the recorded weight became the new Baseline weight. Trastuzumab emtansine was provided as a single-use lyophilized formulation.
Study NCT01419197 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment of physician's choice
Description: The treatment of physician's choice (TPC) was a protocol-specified approved or standard of care therapy or combination of therapies, based on frequently used regimens for late-line HER2-positive metastatic breast cancer treatment after receipt of both trastuzumab- and lapatinib-containing regimens. The therapies included single-agent chemotherapy, single-agent (e.g., tamoxifen or aromatase inhibitor) or dual-agent (e.g., aromatase inhibitor with luteinizing hormone releasing hormone \[LHRH\] agonist) hormonal therapy for hormone receptor positive-disease, and HER2-directed therapy.~Participants who had documented progressive disease (PD) were eligible to switch treatment to receive trastuzumab emtansine 3.6 mg/kg. Participants who switched treatment remained on trastuzumab emtansine treatment until another PD event or unmanageable toxicity.~The formulation, storage, and preparation of all TPC were as per the appropriate package insert or national prescribing information.
Study NCT01658306 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: remote ischemic preconditioning
Description: RIPC consists of five 5-min cycles of right upper arm ischemia/reperfusion, induced by an automated cuff-inflator placed on the right upper arm which is inflated to 200 mmHg for 5mins followed by deflating the cuff for 5mins, each patient in the RIPC group will have the treatment twice a day for two weeks.
Study NCT01658306 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham remote ischemic preconditioning
Description: Sham RIPC consists of five 5-min cycles of right upper arm ischemia/reperfusion, induced by an automated cuff-inflator placed on the right upper arm which is inflated to 50 mmHg for 5mins followed by deflating the cuff for 5mins, each patient in the placebo RIPC group will have the treatment twice a day for two weeks.
Study NCT02366884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Bacterial Agents
Description: Doxycycline, Paramomycin, Clarithromycin, Clindamycin, Dapsone, Miltefosine
Study NCT02366884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Fungal Agents
Description: Itraconazole, Amphotericin B liposomal, Fluconazole, Terbinafine, Voriconazole
Study NCT02366884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Protozoal Agents
Description: Nitazoxanide, Chloroquine, Albendazole, Ivermectin, Mebendazole, Metronidazole, Praziquantel, Levamisole
Study NCT00636363 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bausch & Lomb Multipurpose Solution - Rub Care
Description: Daily care for contact lenses - rub care regimen
Study NCT00636363 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bausch & Lomb Multipurpose Solution - No Rub Care
Description: Daily care for contact lenses - no rub care regimen
Study NCT00636363 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ciba Vision Aquify Multipurpose Solution
Description: daily care for contact lenses
Study NCT03368690 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oligopin®
Description: At the treatment period (0th to 4th week of the experiment), subjects with ADHD will receive 1\~3 capsules of polyphenolic extract from pine bark (25mg or 50 mg Oligopin per capsule) according to their body weight and age. The 5th to 6th week will be the washout period. The control group and Oligopin group will be cross-over at 7th week to 10th week of the experiment.
Study NCT03368690 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: At the treatment period (0th to 4th week of the experiment), subjects with ADHD will receive 1\~3 capsules of polyphenolic extract from pine bark (25mg or 50 mg Oligopin per capsule) according to their body weight and age. The 5th to 6th week will be the washout period. The control group and Oligopin group will be cross-over at 7th week to 10th week of the experiment.
Study NCT02316405 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm and Leg Cycling Exercise for Walking after Stroke
Study NCT01473797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Subcutaneous injections, 0,1 mg/kg/day for 5 days, one course per month for 4 months
Study NCT02068547 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: locally harvested autograft, demineralized bone matrix, and cadaveric allograft
Study NCT02068547 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspirate
Study NCT02831673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG)
Description: DTG is available as 50 mg white, round, biconvex, film coated tablet debossed on one side with 'SV 572' and on the other side with '50'. The tablets are packaged into high density polyethylene (HDPE) bottles with induction seals and child resistant closures. Each 45 ml bottle contains 30 tablets and a desiccant. DTG 50 mg tablet will be orally administered once daily with or without food upto 148 weeks.
Study NCT02831673 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dolutegravir (DTG)
Description: DTG is available as 50 mg white, round, biconvex, film coated tablet debossed on one side with 'SV 572' and on the other side with '50'. The tablets are packaged into high density polyethylene (HDPE) bottles with induction seals and child resistant closures. Each 45 ml bottle contains 30 tablets and a desiccant. DTG 50 mg tablet will be orally administered once daily with or without food upto 148 weeks.
Study NCT02831673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine (3TC)
Description: Lamivudine is available as swedish orange, 'AA' sized elongated double blind HPMC capsules containing 300 mg lamivudine to visually match overencapsulated TDF/FTC FDC tablet. The capsules are packaged into HDPE bottles with induction seals and child resistant closures. Each 150 mL bottle contains 30 capsules and a desiccant. Overencapsulated 3TC 300 mg tablet will be orally administered once daily with or without food upto 96 weeks. From Week 96 to Week 148, lamivudine will be dispensed as 300 mg white, diamond shaped, scored, film coated tablets debossed with 'GX CJ7' on both sides, packed in over labelled HDPE bottles with child-resistant closures each containing 30 tablets.
Study NCT00796991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Solution, intravenous, 10mg/kg, every 3 weeks in the induction phase, up to 4 doses in the induction phase, 48 weeks
Study NCT00796991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Solution, intravenous, Area Under the Concentration Time Curve=6, every 3 weeks in the induction phase, up to 8 doses in the induction phase, 48 weeks
Study NCT00796991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Solution, intravenous, 175 mg/m2, every 3 weeks in the induction phase, up to 8 doses in the induction phase, 48 weeks
Study NCT00796991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Description: Solution, intravenous, 850 mg/m2, every 3 weeks in the induction phase, up to 8 doses in the induction phase, 48 weeks
Study NCT06033755 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Norwegian psychomotor physiotherapy
Description: The intervention consisted predominantly of Norwegian Psychomotor Physiotherapy (NPMP) in which participants received individually tailored treatment based on the body examination and reported respiratory distress. NPMP addresses bodily tension, postural de-alignments and dysfunctional breathing patterns. The consultations also included a cognitive dimension, that is a conversation, in which thoughts and behaviours about training and competing were addressed and where participants were provided with self help measures that could improve breathing during training and competing. A rehabilitation plan for each participant was designed to limit further impairments and maintaining aerobic capacity without intensifying EILO symptoms. The intervention lasted 5 months.
Study NCT01614678 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B contact lens with color, automated
Description: Silicone hydrogel contact lens with color manufactured via an automated process
Study NCT01614678 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B contact lens with color, semi-automated
Description: Silicone hydrogel contact lens with color manufactured via a semi-automated process
Study NCT00572767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextro-Amphetamin
Description: After a two week baseline phase the patients will receive a dose of 10mg Dexamphetamine on two days per week for five weeks. Within a time frame of one to three hours they should receive physiotherapy focusing on neurodevelopmental (NDT) for one hour.
Study NCT00572767 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Glucose
Description: After a two week baseline phase the patients will receive a dose of 10mg of a placebo (same appearance as the experimental drug) on two days per week for five weeks. Within a time frame of one to three hours they should receive physiotherapy focusing on neurodevelopmental (NDT) for one hour.~The treatment of the control group will be the same as for the experimental group except the content of the drug capsule.
Study NCT05979142 — intervention group
Intervention type: OTHER
Intervention: community-based primary care program
Description: See group description
Study NCT03376295 — intervention group
Intervention type: DRUG
Intervention: LABA and the LAMA tiotropium (LABA-TIO)
Description: combinational drug
Study NCT03376295 — intervention group
Intervention type: DRUG
Intervention: LABA and an ICS (LABA-ICS)
Description: combinational drug